down arrow

Exicure, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30205M2008
USD
6.74
1.2 (21.66%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.236.79

52 Week

3.1026.67
Valuation
Technical
Day's Volume

CASH

70.53 k

Shareholding (Dec 2024)

FII

9.30%

Held by 3 FIIs

DII

80.74%

Held by 1 DIIs

Promoter

9.27%

How big is Exicure, Inc.?

22-Jun-2025

As of Jun 18, Exicure, Inc. has a market capitalization of 52.56 million, with net sales of 0.50 million and a net profit of -9.70 million over the last four quarters. The company reported shareholder's funds of 6.77 million and total assets of 15.06 million as of Dec 24.

Market Cap: As of Jun 18, Exicure, Inc. has a market capitalization of 52.56 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Exicure, Inc. reported net sales of 0.50 million and a net profit of -9.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.77 million and total assets of 15.06 million.

Read More

What does Exicure, Inc. do?

22-Jun-2025

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics using its Spherical Nucleic Acid technology for immuno-oncology and genetic disorders, with a market cap of $52.56 million and a recent net profit of -$7 million.

Overview:<BR>Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immuno-oncology, genetic disorders, and other indications based on its Spherical Nucleic Acid (SNA) technology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -7 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 52.56 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.74 <BR>Return on Equity: -41.72% <BR>Price to Book: 7.76 <BR><BR>Contact Details:<BR>Address: 2430 N. HALSTED ST., CHICAGO IL : 60614 <BR>Tel: ['1 847 6731700', '1 781 2353060'] <BR>Fax: 1 847 5566411 <BR>Website: http://www.exicuretx.com/

Read More

Who are in the management team of Exicure, Inc.?

22-Jun-2025

As of March 2022, the management team of Exicure, Inc. includes Timothy Walbert (Independent Chairman), Dr. David Giljohann (CEO and Director), Dr. Chad Mirkin, James Sulat, Dr. Jeffrey Cleland, Bosun Hau, and Helen Kim (all Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Exicure, Inc. includes the following individuals:<BR><BR>- Mr. Timothy Walbert, who serves as the Independent Chairman of the Board.<BR>- Dr. David Giljohann, who is the Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, and a Director.<BR>- Dr. Chad Mirkin, who is a Director.<BR>- Mr. James Sulat, who is also a Director.<BR>- Dr. Jeffrey Cleland, who serves as an Independent Director.<BR>- Mr. Bosun Hau, who is an Independent Director.<BR>- Ms. Helen Kim, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Exicure, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Exicure, Inc. is significantly overvalued with a P/B ratio of 10.08 and negative financial metrics, leading to a downgrade in its valuation grade and a year-to-date stock decline of 52.45%, contrasting sharply with its peers and the S&P 500.

As of 9 February 2024, Exicure, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its P/B ratio of 10.08 and negative metrics such as an EV to EBITDA of -13.68 and an ROE of -41.72%. <BR><BR>When compared to peers, Exicure's valuation metrics are less favorable; for instance, Benitec Biopharma, Inc. has an EV to EBITDA of -10.1454, and Monopar Therapeutics, Inc. stands at -8.7189. The stark contrast in performance is further underscored by Exicure's poor stock performance, with a year-to-date decline of 52.45% compared to a modest 2.44% gain in the S&P 500. Overall, the financial ratios and peer comparisons suggest that Exicure, Inc. is significantly overvalued in the current market.

Read More

Is Exicure, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Exicure, Inc. is in a bearish trend with weak strength, indicated by negative MACD, RSI, and moving averages, and has underperformed the S&P 500 with a year-to-date return of -71.62% compared to the S&P's 12.22%.

As of 2 September 2025, the technical trend for Exicure, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, both the Bollinger Bands and KST are bearish on the weekly timeframe. <BR><BR>In terms of multi-period returns, Exicure has significantly underperformed the S&P 500, with a year-to-date return of -71.62% compared to the S&P's 12.22%, and a 5-year return of -98.74% against the S&P's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 27 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.83

stock-summary
Return on Equity

-75.44%

stock-summary
Price to Book

3.07

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.38%
0%
31.38%
6 Months
-35.0%
0%
-35.0%
1 Year
-51.86%
0%
-51.86%
2 Years
186.75%
0%
186.75%
3 Years
36.55%
0%
36.55%
4 Years
-89.42%
0%
-89.42%
5 Years
-96.88%
0%
-96.88%

Exicure, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Exicure, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Exicure, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, both the Bollinger Bands and KST are bearish on the weekly timeframe. In terms of multi-period returns, Exicure has significantly underperformed the S&P 500, with a year-to-date return of -71.62% compared to the S&P's 12.22%, and a 5-year return of -98.74% against the S&P's 96.61%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
9.59%
EBIT to Interest (avg)
-16.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
1.28
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.70%
ROCE (avg)
94.11%
ROE (avg)
105.78%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.08
EV to EBIT
-11.41
EV to EBITDA
-13.68
EV to Capital Employed
-11.26
EV to Sales
56.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-41.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.7%)

Foreign Institutions

Held by 3 Foreign Institutions (9.3%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -186.67% vs 141.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-2.90",
          "chgp": "20.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "5.80",
          "chgp": "-103.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.60",
          "val2": "3.00",
          "chgp": "-186.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 42.60% vs -550.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-12.70",
          "chgp": "67.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.90",
          "val2": "-2.00",
          "chgp": "-245.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.70",
          "val2": "-16.90",
          "chgp": "42.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,898.00%",
          "val2": "0.00%",
          "chgp": "-989.80%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.30
-2.90
20.69%
Interest
0.00
0.00
Exceptional Items
-0.20
5.80
-103.45%
Consolidate Net Profit
-2.60
3.00
-186.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -186.67% vs 141.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.00
Operating Profit (PBDIT) excl Other Income
-4.10
-12.70
67.72%
Interest
0.00
0.00
Exceptional Items
-6.90
-2.00
-245.00%
Consolidate Net Profit
-9.70
-16.90
42.60%
Operating Profit Margin (Excl OI)
-9,898.00%
0.00%
-989.80%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 42.60% vs -550.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Exicure, Inc. stock-summary
stock-summary
Exicure, Inc.
Pharmaceuticals & Biotechnology
Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).
Company Coordinates stock-summary
Company Details
2430 N. HALSTED ST. , CHICAGO IL : 60614
stock-summary
Tel: 1 847 67317001 781 2353060
stock-summary
http://www.exicuretx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."